ICCC: ImmuCell Corporation Stock

by  •  • Comments Off on ICCC: ImmuCell Corporation Stock

SIC 2835 – In Vitro and In Vivo Diagnostic Substances

Valuation
Market Cap ($M) 43.40
Enterprise Value ($M) 50.49
Book Value ($M) 26.41
Book Value / Share 2.96
Price / Book 1.64
NCAV ($M) -4.15
NCAV / Share -0.47
Price / NCAV -10.46

Profitability (mra)
Return on Invested Capital (ROIC) -0.05
Return on Assets (ROA) -0.05
Return on Equity (ROE) -0.08

Liquidity (mrq)
Quick Ratio 1.44
Current Ratio 3.11

Balance Sheet (mrq) ($M)
Current Assets 13.89
Assets 44.45
Liabilities 18.04
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 26.49
Operating Income -1.64
Net Income -2.16
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
09-17 13D/A Srk Fund I, Lp. 6.40 28.35
08-27 13D Knudsen Ejnar A III 5.90

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 (Commission file number) Imm
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 (Commission file number) ImmuCell
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 (Commission file number) ImmuCel
2024-04-01 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 (Commission file number) ImmuCell Corpo

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-11 1,645 10,899 15.09
2025-03-10 237 36,034 0.66
2025-03-07 21 12,007 0.17
2025-03-06 248 3,444 7.20

(click for more detail)

Similar Companies
HOTH – Hoth Therapeutics, Inc. HRTX – Heron Therapeutics, Inc.
IBIO – iBio, Inc. IKT – Inhibikase Therapeutics, Inc.
IMCC – IM Cannabis Corp.


Financial data and stock pages provided by
Fintel.io